SAMLYN CAPITAL LLC 13D and 13G filings for Corvus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 1:53 pm Purchase | 2024-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | SAMLYN CAPITAL LLC | 6,667,105 9.800% | 403,347 (+6.44%) | Filing |
| 2024-08-01 9:18 pm Sale | 2024-08-01 | 13G | Corvus Pharmaceuticals, Inc. CRVS | SAMLYN CAPITAL LLC | 6,263,758 9.990% | -4,226 (-0.07%) | Filing |
| 2024-05-13 4:52 pm Purchase | 2024-05-01 | 13G | Corvus Pharmaceuticals, Inc. CRVS | SAMLYN CAPITAL LLC | 6,267,984 9.990% | 3,771,725 (+151.10%) | Filing |
| 2024-02-14 1:31 pm Purchase | 2023-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | SAMLYN CAPITAL LLC | 2,496,259 5.100% | 2,496,259 (New Position) | Filing |